The histone deacetylase inhibitors global market report 2024 from The Business Research Company provides comprehensive market statistics, including global market size, regional shares, competitor market share, detailed segments, trends, and opportunities. This report offers an in-depth analysis of current and future industry scenarios, delivering a complete perspective for thriving in the industrial automation software market.
Histone Deacetylase Inhibitors Market, 2024 report by The Business Research Company offers comprehensive insights into the current state of the market and highlights future growth opportunities.
Market Size –
The histone deacetylase inhibitors market size has grown strongly in recent years. It will grow from $1.12 billion in 2023 to $1.20 billion in 2024 at a compound annual growth rate (CAGR) of 7.9%. The growth in the historic period can be attributed to regulatory support and fast-track approvals, the growing prevalence of cancer, increased funding for cancer research, the expansion of therapeutic applications, and increased expenditure on healthcare infrastructure.
The histone deacetylase inhibitors market size is expected to see strong growth in the next few years. It will grow to $1.64 billion in 2028 at a compound annual growth rate (CAGR) of 8.0%. The growth in the forecast period can be attributed to growing investment in biotechnology, the growing elderly population, favorable regulatory approvals and faster drug approval processes, improved drug delivery systems, and the expansion of therapeutic applications. Major trends in the forecast period include the integration of wearable devices to monitor patient health, innovations in nanotechnology and drug delivery methods, advances in identifying and validating biomarkers, artificial intelligence (AI) and machine learning, and next-generation sequencing.
Order your report now for swift delivery @
https://www.thebusinessresearchcompany.com/report/histone-deacetylase-inhibitors-global-market-report
Scope Of Histone Deacetylase Inhibitors Market
The Business Research Company’s reports encompass a wide range of information, including:
1. Market Size (Historic and Forecast): Analysis of the market’s historical performance and projections for future growth.
2. Drivers: Examination of the key factors propelling market growth.
3. Trends: Identification of emerging trends and patterns shaping the market landscape.
4. Key Segments: Breakdown of the market into its primary segments and their respective performance.
5. Focus Regions and Geographies: Insight into the most critical regions and geographical areas influencing the market.
6. Macro Economic Factors: Assessment of broader economic elements impacting the market.
Histone Deacetylase Inhibitors Market Overview
Market Drivers –
The increasing incidence of cancer is expected to propel the growth of the histone deacetylase inhibitors market going forward. The rising incidence of cancer is primarily attributed to aging populations, increased exposure to risk factors such as tobacco, diet, and environmental pollutants, and improved diagnostic techniques leading to earlier and more frequent detection. Histone deacetylase inhibitors treat cancer by altering chromatin structure, leading to the activation of tumor suppressor genes and suppression of oncogenes, thereby inducing cell cycle arrest and apoptosis in cancer cells. For instance, in February 2024, according to the World Health Organization, a US-based intergovernmental organization, approximately 35 million new cancer cases were predicted in 2050, a 77% increase from the estimated 20 million cases in 2022. Therefore, the increasing incidence of cancer is driving the growth of the histone deacetylase inhibitors market.
Market Trends –
Major companies operating in the histone deacetylase inhibitors market are focusing on developing innovative product formulations, such as oral histone deacetylase (HDAC) inhibitors, to expand treatment options and improve patient convenience and compliance. An oral histone deacetylase (HDAC) inhibitor is a drug taken by mouth that targets HDAC enzymes involved in gene regulation and is potentially used in treating various diseases, including cancer and inflammatory conditions. For instance, in March 2024, Italfarmaco S.p.A., an Italy-based pharmaceutical company, received Food and Drug Administration approval for Duvyzat (givinostat), an oral histone deacetylase (HDAC) inhibitor, for the treatment of Duchenne muscular dystrophy (DMD) in patients aged 6 years and older. Duvyzat is a histone deacetylase (HDAC) inhibitor that mitigates the sequence of events leading to muscle damage, potentially slowing the progression of muscle deterioration associated with DMD. By inhibiting HDAC overactivity, it reduces inflammation and fibrosis while promoting muscle fiber regeneration. The approval is based on the pivotal phase 3 EPIDYS trial, which met its primary endpoint, demonstrating that patients on Duvyzat showed a statistically significant decrease in the time to complete the four-stair climb assessment compared to placebo.
The histone deacetylase inhibitors market covered in this report is segmented –
1) By Classification: Class I Histone Deacetylases (HDACs), Class II Histone Deacetylases (HDACs), Class III Histone Deacetylases (HDACs), Other Classifications
2) By Route Of Administration: Oral, Injectable, Other Routes Of Administration
3) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy, Other Distribution Channels
4) By Application: Oncology, Neurology, Other Applications
5) By End Users: Hospitals, Homecare, Specialty Clinics, Other End Users
Get an inside scoop of the histone deacetylase inhibitors market, Request now for Sample Report @
https://www.thebusinessresearchcompany.com/sample.aspx?id=17170&type=smp
Regional Insights –
North America was the largest region in the histone deacetylase inhibitors market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the histone deacetylase inhibitors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Key Companies –
Major companies operating in the histone deacetylase inhibitors market are Merck & Co. Inc., AstraZeneca plc, Novartis AG, Eisai Co. Ltd., Aurobindo Pharma Limited, Karyopharm Therapeutics Inc., Syndax Pharmaceuticals Inc., MEI Pharma Inc., Italfarmaco S.p.A., Tokyo Chemical Industry Co. Ltd., InvivoGen Corp., Huya Bioscience International LLC, Crystal Genomics Inc., Spectrum Pharmaceuticals Inc., Curis Inc., Celgene Corporation, Celleron Therapeutics, Medivir AB, Onxeo SA, Regenacy Pharmaceuticals Inc., Shenzhen Chipscreen Biosciences Co. Ltd., Wellness Pharma International LLC, Forum Pharmaceuticals Inc., Midatech Pharma PLC
Table of Contents
1. Executive Summary
2. Histone Deacetylase Inhibitors Market characterstics
3. Histone Deacetylase Inhibitors Market Trends And Strategies
4. Histone Deacetylase Inhibitors Market – Macro Economic Scenario
5. Global Histone Deacetylase Inhibitors Market Size And Growth
…..
32. Global Histone Deacetylase Inhibitors Market Competitive Benchmarking
33. Global Histone Deacetylase Inhibitors Market Competitive Dashboard
34. Key Mergers And Acquisitions In The Histone Deacetylase Inhibitors Market
35. Histone Deacetylase Inhibitors Market Future Outlook and Potential Analysis
36. Appendix
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
